★ Vecino
Introduce some new drugs developed in China, and there are more than 20 new drugs in clinical trials (NCE or traditional Chinese medicine). I hope you can add other new drug information.
★ Bicyclic alcohol tablets (Bicyclic alcohol)
The trade name "Vecino" is a product jointly developed by China Academy of Medical Sciences and Peking Union Medical College. It is the first innovative anti-hepatitis synthetic drug with independent intellectual property rights in China.
19961February entered the clinical trial with the approval of the Ministry of Health, and obtained the new drug certificate and production approval number issued by the former National Medical Products Administration on September 5438+00, 2006, which was produced and listed by Peking Union Medical College Pharmaceutical Factory. At present, it has obtained 20 years of invention patent protection in 16 countries and regions in the world, and enjoys the administrative protection period of 12 in China.
This product is a drug screened by chemical synthesis on the basis of enzyme-lowering drugs bifendate and Schisandra chinensis. Its good dual mechanism can scavenge free radicals to protect cell membrane, protect DNA immune damage of hepatocytes and reduce the occurrence of apoptosis. Clinical results show that it has good inhibitory effect on hepatitis B virus, good safety, low toxicity and no mutagenic adverse reaction, and is suitable for mild to moderate chronic hepatitis. Clinical long-term efficacy is better than bifendate, and it has become one of the first choice drugs to treat chronic viral hepatitis.
★ April
Ipril is a new type of selective inhibitor of 5α- reductase, which was jointly developed by China Pharmaceutical University, Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences and Yangzhou Pharmaceutical Factory in July 1993, and was listed as a key scientific and technological project by the state in June/996.
1996, Ipril was allowed to enter the clinical research stage, and in August of 1999, it obtained the new drug certificate and production approval of raw materials and tablets issued by the former National Medical Products Administration, which was confirmed in 200 1 year. Now it has become the leading product of Lianhuan Pharmaceutical and enjoys the exclusive production protection period of 12.
The medicine can inhibit the transformation process of testosterone, reduce the content of dihydrotestosterone in prostate, lead to the atrophy of benign prostatic hyperplasia, and thus improve the symptoms of dysuria in patients with benign prostatic hyperplasia, which is safe and reliable. According to the requirements of the national first-class new drug, the drug has achieved satisfactory results in the open phase IV clinical research. The drug has been listed in the national basic medical insurance drug list, and the market share of epristeride products will gradually increase after listing.
Epril can selectively inhibit 5α- reductase, and its inhibition selectivity is better than finasteride, with few adverse reactions. It is a safe and effective drug and a highly competitive therapeutic drug.
★ Enbipu
The main component of "Enbip" is butylphthalide, which is jointly developed by the Institute of Pharmacology of China Academy of Medical Sciences and Shijiazhuang Pharmaceutical Group Co., Ltd. It is a new drug with independent intellectual property rights in the field of cardiovascular and cerebrovascular diseases in China and has won two national patents.
"Enbipu" is suitable for treating ischemic stroke (commonly known as stroke), and its main component butylphthalide has the same structure as apigenin A extracted from celery seeds. The listing of this product will become a new benefit growth point for Unocom.
★ Hematoporphyrin injection
Hematoporphyrin is the first photosensitizer in China, which belongs to a new class of drugs and is a new drug for the treatment of malignant tumors. It is called "photochemical missile". In 2003, Chongqing Huading Modern Biopharmaceutical Co., Ltd. obtained the production approval issued by the former National Medical Products Administration, exclusively produced and listed under the trade name "Xipo Powder".
After the drug enters the human body through intravenous drip, it reaches the malignant tumor tissue with blood circulation, and accumulates and stays in it. Subsequently, when these tumors are irradiated by laser with a specific wavelength, their drugs undergo photochemical reaction, producing monovalent oxygen, which directly kills malignant tumor tissues, and the whole process has no damage to normal human tissues. Whether it is for primary cancer or recurrent cancer, it can achieve the purpose of cure or improvement, and at the same time alleviate the disability pain of patients.
At the same time, the drug is also used for localized diagnosis and treatment of cancer, which has the characteristics of strong selectivity, little damage to normal tissues and little side effects. The clinical localization diagnosis rate of cancer is 9 1%.
★ Sodium glycididazole
Sodium glycididazole (CMNa) is a new type of anti-cancer sensitizer and an innovative drug with independent intellectual property rights designed and developed by China. In 2002, Guangzhou Laitai Pharmaceutical Co., Ltd. obtained the certificate and production approval of a new drug issued by the former National Medical Products Administration, and exclusively produced and listed under the trade name "Ximena".
Sodium glycididazole is an innovative chemical synthetic drug, and it is the only low-toxicity and high-efficiency chemotherapy sensitizer listed in the world at present. The drug was initiated by the Radiation Research Office of the Second Military Medical University in 1983, and was granted the invention patent right by the State Patent Office in September 1993. At the beginning of 2000, this patent won the invention gold medal awarded by China National Intellectual Property Administration and the World Intellectual Property Organization.
Clinical research shows that sodium glycididazole has a good therapeutic effect in anti-cancer treatment and has a broad market prospect.
★ rmhTNF
Recombinant human tumor necrosis factor for injection (rmhTNF) is a recombinant human tumor necrosis factor for injection developed and produced by Shanghai Saida Biopharmaceutical Co., Ltd., and its trade name is "Nakosi". On April 24th, 2003, RMH tumor necrosis factor (TNF) was certified as a new drug, and it was the first systemic TNF variant approved for marketing in the world.
Nacox is called by experts as the most inspiring anti-tumor drug found at present, which has remarkable curative effect on many malignant tumors, especially respiratory malignant tumors. Its mechanism of action is as follows: directly killing tumor cells; Destroy the blood supply of tumor tissue; Mediate the immune regulation of the body; Enhance the sensitivity of radiotherapy and chemotherapy. The product is expected to get better economic benefits after it is put on the market.
★ Pioglitazone
Insulin resistance refers to the insensitivity or decreased sensitivity of human insulin effector tissues to insulin, which is considered as the root cause of type 2 diabetes and its complications. Pioglitazone hydrochloride is a new generation of insulin sensitizer, and its mechanism is to enhance the sensitivity of peripheral tissues to insulin, reduce insulin resistance, and thus reduce blood sugar. Pioglitazone hydrochloride is the only ketone drug approved by FDA in the United States that can be used in combination with insulin and sulfonylureas.
At present, pioglitazone hydrochloride raw materials and tablets (trade name: Aiting) jointly developed by China Pharmaceutical R&D Center and Beijing Taiyang Pharmaceutical Co., Ltd. are sold in China. Raw materials and tablets of Dalian Yuanda Pharmaceutical Co., Ltd., Jiangsu No.1 Pharmaceutical Co., Ltd., Bao Li Biopharmaceutical Co., Ltd., Beijing Xinghao Modern Co., Ltd., Shanghai Fosun Zhao Hui Co., Ltd., Shanghai Institute of Medical Engineering, jiangsu hengrui Pharmaceutical Co., Ltd. and Henan Xinxiang Lianyi Pharmaceutical Co., Ltd.; Capsules of Shandong Zibo Xinda Pharmaceutical Co., Ltd., Bao Li Biopharmaceutical, Beijing Xinghao Modern and Shenyang Jinlong; Jiangsu hengrui Pharmaceuticals and Tablets (trade name: Ruitong) of Shanghai Pharmaceutical Industry Research Institute have successively obtained the national first-class new drug certificates, and have been fully applied in clinic.
★ Naftopidil tablets
Naftopidil tablet is a new type of antihypertensive drug (trade name: Bodi) independently developed by Guizhou Yikang Pharmaceutical Group for 8 years, which has independent intellectual property rights in China. 200 1 may. It is said to be the first class of chemically synthesized new drugs in China, thus ending the history that there is no new class of chemically synthesized antihypertensive drugs in China.
Naftopidil tablet has its own unique advantages in the treatment of hypertension: it is a superselective α 1- adrenergic receptor blocker, which has the functions of 5-HT 1A receptor agonist and Ca2 ++ channel antagonist; With multiple antihypertensive mechanisms, it can effectively control blood pressure, avoid adverse reactions such as postural hypotension and reflex tachycardia with "first dose effect", have a benign effect on blood lipid and blood glucose metabolism, and can improve dysuria caused by prostatic hypertrophy. It is a safe and effective new drug for long-term treatment of hypertension.
At present, in the research and development of naftopidil tablets in China, Nanjing No.2 Pharmaceutical Factory, Nanjing Meirui Pharmaceutical (trade name: NATO) and Hainan Haifu Pharmaceutical Co., Ltd. have also obtained the approval documents for the first-class new drugs of raw materials or tablets.
★ Artemisinin
The research results are a successful example of carrying forward the treasure house of Chinese medicine in China, and also a successful example of scientific research and innovation by researchers of China Academy of Sciences aiming at the major needs of the country. At present, the researchers of Institute of Medicine have applied to the Ministry of Science and Technology for the research project of artemisinin anti-blood worm and anti-cancer drugs, and are paying close attention to the further research of artemisinin.
★ Boanmycin (Boanmycin)
Boanmycin, a new class of anti-tumor antibiotics, is the first one in China. Boanmycin, formerly known as Actinomycin A6, is produced by Streptomyces verticillatus. A new species of Pingyang, belonging to bleomycin (B 1eomycin) family. Boanmycin and bleomycin (b 1 oxytocin) have the same anti-tumor spectrum. After nearly 20 years' efforts, it passed the new drug evaluation center and expert evaluation of the State Administration of Pharmaceutical Products, and obtained the first-class new drug certificate.
★ Retinoic acid in the treatment of leukemia (APL)
★ Arsenic trioxide for leukemia (APL, MDS, MM)
★ Jing En Rich (NOBEX)
The component is mouse nerve growth factor (mNGF), which is supported by the Ninth Five-Year National Science and Technology Key Program and listed as a high-tech industrialization demonstration project of the State Planning Commission, and also a national torch project in 2002. It is a national first-class new drug (biopharmaceutical) jointly developed by Xiamen Peking University Road Bioengineering Co., Ltd. and Lanzhou Institute of Biological Products of the Ministry of Health. The indication is toxic nerve injury caused by cyclohexane. Can be used for treating various nerve injuries.